Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Top Links You Must Click On


Response Genetics, Inc. Announces Third Quarter Financial Results
--- Revenue increases to $5.4 million ---

LOS ANGELES, Nov. 13, 2012 /PRNewswire/ -- Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests for helping determine a patient's response to cancer therapy, today announced its consolidated financial results for the third quarter ended September 30, 2012.

Total revenues for the quarter ended September 30, 2012 increased to $5.40 million, compared to $3.84 million for the quarter ended June 30, 2012 and $5.10 million for the quarter ended September 30, 2011.  The Company's pharmaceutical client revenue increased by $1.37 million and the ResponseDX® revenue increased by $189 thousand relative to the quarter ended June 30, 2012. 

The Company's net loss for the quarter ended September 30, 2012 decreased by $1.3 million to $1.4 million compared to a net loss of $2.7 million for the quarter ended June 30, 2012 and a net loss of $1.4 million for the quarter ended September 30, 2011.  This is the third consecutive quarter the Company decreased its net loss. 

The Company also increased its gross margin in three consecutive quarters from approximately 25% for the fourth quarter of 2011, to approximately 32% for the quarter ended March 31, 2012 to approximately 37% for the quarter ended June 30, 2012, to approximately 49% for the quarter ended September 30, 2012.  Gross margin is Net Revenue less Cost of Revenue.

Excluding cost of revenue, total operating expenses for the third quarter were $4.0 million, compared to $4.1 million for the quarter ended June 30, 2012 and $4.0 million for the same period last year.

"We are very pleased with the financial results for the quarter ended September 30, 2012, which improved again relative to the prior quarter.  Since the fourth quarter of last year, we continued to realize consecutive quarter-over-quarter positive results from the many changes implemented by the Company.  Gross margins have increased nearly two-fold from the fourth quarter of last year, and operating loss has continued to decrease significantly, or nearly two-fold, since last quarter and by a factor of nearly 2.8 from the fourth quarter of last year," said Thomas Bologna, the Company's Chairman & Chief Executive Officer.

Total revenues for the nine months ended September 30, 2012 were $13.2 million compared to $17.7 million for the nine months ended September 30, 2011.  The decrease is largely a result of the expected decrease in pharmaceutical client revenue of $3.9 million from $8.3 million for the nine months ended September 30, 2011 to $4.4 million for the nine months ended September 30, 2012. Additionally, early in 2012, the Company made the strategic decision to focus much of its pharmaceutical resources on working with GSK as it moves its drugs, for which the Company did extensive patient testing, through the FDA approval process.  The Company's ResponseDX® revenue was $8.8 million for the nine months ended September 30, 2012, compared to $9.4 million for the nine months ended September 30, 2011, largely as a result of tactical changes the Company is undergoing in building and directing its sales force. 

The Company's net loss for the nine months ended September 30, 2012 was $7.3 million, compared with a net loss of $1.8 million for the nine months ended September 30, 2011. 

Excluding cost of revenue, total operating expenses for the nine months were $12.5 million, compared to $11.4 million for the same period last year.  The increase in total operating expense of $1.1 million was due to an increase in general and administrative expenses of $0.2 million and an increase in research and development expenses of $0.9 million.

The Company's cash position increased substantially to $10.8 million at September 30, 2012 compared to $2.6 million at June 30, 2012.

Mr. Bologna concluded, "In the third quarter we also increased our cash position significantly to nearly $11,000,000.  Today we have a strong balance sheet coupled with steady and consecutive quarter-over-quarter financial performance.  Going forward, we believe we are well positioned, both strategically and financially, to continue building a strong organization to capitalize on the promise of personalized medicine."

Conference Call Details 

To access the conference call by phone on November 13 at 10:00 a.m. EST, dial (800) 537-0745 or (253) 237-1142 for international participants.  A telephone replay will be available beginning approximately two hours after the call through November 20, 2012, and may be accessed by dialing (855) 859-2056 or (404) 537-3406.  The conference passcode for both the live call and replay is 57580014. 

To access the live and archived webcast of the conference call, go to the Investor Relations section of the Company's Web site at http://investor.responsegenetics.com.  It is advised that participants connect at least 15 minutes prior to the call to allow for any software downloads that might be necessary.

About Response Genetics, Inc.
Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer.  The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens.  The Company's principal customers include oncologists and pathologists.  In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry.  The Company's headquarters is located in Los Angeles, California.  For more information, please visit www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company, to provide clinical testing services to the medical community, to continue to strengthen and expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to continue to strengthen marketing capabilities, to expand the suite of ResponseDX® products, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, to continue to execute on its business strategy and operations, to continue to analyze cancer samples and the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "project," "may," "could," "would," "should," "believe," "expect," "anticipate," "estimate," "intend," "plan" or similar expressions.

These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities Exchange Commission.  Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

Investor Relations Contact:

Company Contact:

Peter Rahmer

Thomas A. Bologna

Trout Group

Chairman & Chief Executive Officer

646-378-2956

323-224-3900


                                                                                                                             

RESPONSE GENETICS, INC.

 

CONDENSED CONSOLIDATED BALANCE SHEETS

 




December 31,



September 30,




2011



2012







(Unaudited)









Cash and cash equivalents


$

1,700,295



$

10,839,201


Accounts receivable, net



4,047,059




4,383,958


Prepaid expenses and other current assets



991,351




447,494


Total current assets



6,738,705




15,670,653











Property and equipment, net



1,045,287




1,026,562


Intangible assets



66,815




464,010


Total assets


$

7,850,807



$

17,161,225




















Accounts payable


$

1,492,526



$

1,348,241


Accrued expenses



3,251,262




2,134,038


Deferred Revenue



-




803,481


Other current liabilities



1,149,253




1,158,821


Total current liabilities



5,893,041




5,444,581











Other liabilities



240,928




122,021


Common stock classified outside of stockholders' equity (deficit)



7,854,682




19,575,724


Total stockholders' equity (deficit)



(6,137,844)




(7,981,101)


Total liabilities, common stock classified outside of stockholders' equity

(deficit) and stockholders' equity (deficit)


$

7,850,807



$

17,161,225


The condensed consolidated balance sheet at December 31, 2011 is derived from the audited consolidated financial statements at the date included in the Company's Form 10-K for the fiscal year ended December 31, 2011.  The condensed consolidated balance sheet at September 30, 2012 is derived from the unaudited financial statements included in the Company's Form 10-Q for the quarter ended September 30, 2012.

 

RESPONSE GENETICS, INC.

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE LOSS

 




Three Months Ended 

September 30,

(Unaudited)


Nine Months Ended

September 30,

(Unaudited)




2011



2012


2011


2012


Net revenue


$

5,100,649



$

5,403,537


$      17,730,785


$     13,220,188


Operating expenses:













   Cost of revenue



2,538,176




2,768,894


8,040,003


7,895,870


   Selling and marketing



1,251,054




1,195,988


4,107,639


4,145,115


   General and administrative



2,268,517




2,407,544


6,493,079


6,686,559


   Research and development



452,734




426,105


838,622


1,695,851


Total operating expenses



6,510,481




6,798,531


19,479,343


20,423,395















Operating loss



(1,409,832)




(1,394,994)


(1,748,558)


(7,203,207)















Other income (expense):













   Interest expense



(5,804)




(20,497)


(11,379)


(66,556)


   Interest income



96




3


162


24















Net loss



(1,415,540)




(1,415,488)


(1,759,775)


(7,269,739)


Unrealized gain (loss) on foreign currency

translation



(25,593)




968


(25,593)


(1,338)


Comprehensive loss


$

(1,441,133)



$

(1,414,520)


$       (1,785,368)


$    (7,271,077)















Net loss per share — basic and diluted


$

(0.07)



$

(0.05)


$                (0.09)


$              (0.29)















Weighted-average common shares — basic and

diluted



19,537,232




26,362,842


18,979,010


24,709,185


The condensed consolidated statement of operations at September 30, 2011 and 2012 are derived from the unaudited financial statements included in the Company's Form 10-Q for the quarter ended September 30, 2012.

 

SOURCE Response Genetics, Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Enterprise Open Source Magazine Latest Stories . . .
MapDB is an Apache-licensed open source database specifically designed for Java developers. The library uses the standard Java Collections API, making it totally natural for Java developers to use and adopt, while scaling database size from GBs to TBs. MapDB is very fast and supports a...
CommVault on Tuesday announced new enhancements to its PartnerAdvantage program designed to help channel partners accelerate revenue growth and simplify collaboration as they expand into new markets, such as data protection, archiving, mobility and cloud services. The expanded program ...
Dell and Red Hat Inc. have announced the availability of co-engineered, enterprise-grade, private cloud solutions based on OpenStack, the Dell Red Hat Cloud Solution, powered by Red Hat Enterprise Linux OpenStack Platform. The companies also have extended their collaboration to enable...
Last week was a crazy week for information security. That's probably also the understatement of the year. With the public exposure of Heartbleed, everyone was talking about what to do and how to do it to help customers and the Internet, in general, deal with the ramifications of such a...
Jelastic on Tuesday announced support for multiple ISV software packages in Jelastic’s products for enterprises, hosting service providers and developers. This support is achieved using OpenShift by Red Hat’s pluggable Cartridge standard, allowing those developers to build application ...
Red Hat on Monday announced OpenShift Marketplace, a one-stop shop that will enable customers to find and try solutions for their cloud applications. The OpenShift Marketplace will bring the power of Red Hat's OpenShift Platform-as-a-Service (PaaS) partner ecosystem directly to OpenShi...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE